Opus Genetics details 2025 progress and 2026 catalysts; cash >$50M, sNDA for presbyopia submitted

Opus Genetics, Inc.

sNDA submitted for phentolamine 0.75% (presbyopia); FDA decision expected by end of 2026.
BEST1 Phase 1/2 initial data this quarter at Macula Society; Cohort 1 3-month results mid-2026.
LCA5 Phase 3 pivotal trial dosing expected in H2 2026 after run-in enrollment.
Cash and equivalents >$50M following $23M equity raise; runway into H2 2027.
One to two preclinical IRD programs (RHO, CNGB1, MERTK, RDH12-LCA, NMNAT1) targeting clinical entry in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.